Peak Bio, Inc. Common Stock
PKBO
PKBO was delisted on the 9th of January, 2023.
24 hedge funds and large institutions have $21.9M invested in Peak Bio, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
60% more funds holding
Funds holding: 15 → 24 (+9)
49% more capital invested
Capital invested by funds: $14.7M → $21.9M (+$7.24M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.96M |
| 2 |
DKCM
Davidson Kempner Capital Management
New York
|
+$1.72M |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$986K |
| 4 |
SCM
Saba Capital Management
New York
|
+$707K |
| 5 |
CM
Cohanzick Management
Pleasantville,
New York
|
+$491K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
-$1.18M |
PKBO Hedge Fund Activity: Q2 2021 in Review
24 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Peak Bio, Inc. Common Stock (PKBO) for Q2 2021, worth a combined $21.9M — up 49% from $14.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PKBO positions and 1 closed out — a net gain of 9 holders — while 7 added to existing stakes and 0 trimmed.
The largest buyer was K2 Principal Fund, adding an estimated $1.96M. The largest seller was Linden Advisors, exiting entirely with an estimated $1.18M sold.
- 24 institutional investors held Peak Bio, Inc. Common Stock (PKBO) as of Q2 2021, up from 15 in Q1 2021.
- Funds reported $21.9M of Peak Bio, Inc. Common Stock stock for Q2 2021, up 49% quarter-over-quarter.
- 10 funds opened new Peak Bio, Inc. Common Stock positions in Q2 2021 and 1 closed out, a net change of +9 holders.
- The largest Peak Bio, Inc. Common Stock buyer in Q2 2021 was K2 Principal Fund, an estimated $1.96M added.
- The largest Peak Bio, Inc. Common Stock seller in Q2 2021 was Linden Advisors, an estimated $1.18M sold.
Based on aggregated 13F filings for Q2 2021.